Phase 2
Completed N=19
A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis
Source: ClinicalTrials.gov NCT03432260 ↗Enrolled (actual)
19
Serious AEs
26.3%
Results posted
Dec 2022
Primary outcomePrimary: Lille Model for Alcoholic Hepatitis Score — 0.020; 0.050; 0.155; 0.195 score on a scale
Summary
This is a research trial testing DUR-928 (an experimental medication). The purpose of this trial is to assess the dose related safety, Pharmacokinetics, and Pharmacodynamics of DUR 928 in patients with moderate and severe alcoholic hepatitis (AH).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Lille Model for Alcoholic Hepatitis Score |
0.020; 0.050; 0.155; 0.195; 0.420 | — |
| PRIMARY Model for End Stage Liver Disease (MELD) Score |
19.5; 19.0; 24.5; 24.5; 25.0; 20.0 | — |
| PRIMARY Model for End Stage Liver Disease (MELD) Score - Percent Change From Baseline |
-5.00; -10.53; 0.00; 0.00; 0.00; -20.00 | — |
| SECONDARY Serum Cytokeratin 18 (M30) |
723.5; 737; 1443.5; 1946; 931; 526 | — |
| SECONDARY Serum Cytokeratin 18 (M65) |
252.5; 1791.0; 3033.5; 4071.5; 1999.0; 353.0 | — |
| SECONDARY International Normalized Ratio (INR) - Percent Change From Baseline |
-10.000; -3.226; 4.768; 0.000; 0.000; -3.676 | — |
| SECONDARY Bilirubin - Percent Change From Baseline |
-15.69; -31.03; -25.19; -6.48; 4.96; -27.27 | — |
Eligibility Criteria
Inclusion Criteria
- Able to provide written informed consent (either from patient or patient's legally acceptable representative)
- Male or female patients 21 years of age or older with BMI ≥ 20 to ≤ 40 kg/m2
- Patients with alcoholic hepatitis defined as:
- History of heavy alcohol abuse: > 40 g/day in females or > 60 g/day in males for a minimum period of 6 months, AND
- Consumed alcohol within 12 weeks of entry into the study, AND
- Serum bilirubin > 3 mg/dL AND AST > ALT, but less than 300 U/L AND
- MELD score between 11-30, inclusive
- No evidence of active infection as determined by the investigator.
- Women of child-bearing potential must utilize appropriate birth control throughout the study duration.
- Male patients must agree to use a medically acceptable method of contraception/birth control throughout the study duration
Exclusion Criteria
- Other or concomitant cause(s) of liver disease as a result of:
- Autoimmune liver disease
- Wilson disease
- Vascular liver disease
- Drug induced liver disease
- Co-infection with human immunodeficiency virus (HIV) or Hepatitis B
- Any active malignancies other than curatively treated skin cancer (basal cell or squamous cell carcinomas)
- If female, known pregnancy, or has a positive serum pregnancy test, or lactating/breastfeeding
- Serum creatinine > 2.5 mg/dL
- Patients who have had organ transplantation (such as liver, kidney, lung, heart, bone marrow, or stem cell etc.), other than cornea transplant
- Stage 3 or greater encephalopathy by West Haven criteria
Data sourced from ClinicalTrials.gov (NCT03432260). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.